ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,572.99
0.58%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Neurocrine Biosciences Inc (NBIX)

  7. Neurocrine Biosciences Inc (NBIX) News

Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NBIX
DateTimeSourceHeadlineSymbolCompany
04/06/202421:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202413:01PR Newswire (US)Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202412:35PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
03/06/202412:30PR Newswire (US)Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of MedicineNASDAQ:NBIXNeurocrine Biosciences Inc
30/05/202421:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
29/05/202421:53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
29/05/202421:01PR Newswire (US)Neurocrine Biosciences to Participate at Investor Conferences in JuneNASDAQ:NBIXNeurocrine Biosciences Inc
28/05/202421:14PR Newswire (US)Neurocrine Biosciences Announces CEO Succession PlanNASDAQ:NBIXNeurocrine Biosciences Inc
28/05/202413:30PR Newswire (US)Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024NASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:34Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202423:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202422:59Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
23/05/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202422:35Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202422:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202422:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202421:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202421:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202421:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
21/05/202421:05PR Newswire (US)Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) CapsulesNASDAQ:NBIXNeurocrine Biosciences Inc
17/05/202421:32Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
17/05/202421:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
17/05/202421:31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NBIXNeurocrine Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:NBIX

Your Recent History

LSE
LLOY
Lloyds Banking
LSE
PANR
Pantheon Resources
LSE
GOLD
LSE
VAST
Vast Resources
LSE
GKP
Gulf Keystone Petroleum
LSE
BIRD
Blackbird
LSE
QBT
Quantum Blockchain Techn...
LSE
ENET
Ethernity Networks
LSE
EEE
Empire Metals
LSE
ARCM
Arc Minerals
LSE
NEXN
Nexxen
LSE
SRSP
Sirius Petroleum
LSE
NSCI
Netscientific
LSE
PHNX
Phoenix
LSE
AFC
Afc Energy
LSE
FUM
Futura Medical
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved